CompletedPhase 3

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

1,086 participantsStarted 2003-07

Plain-language summary

The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.

Who can participate

Age range

18 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Is receiving thiazide diuretic therapy (only to subjects randomized to or receiving febuxostat). * Has a serum urate level less than 8.0 mg/dL and is not taking uric acid-lowering therapy (other than allopurinol or febuxostat). * Has participated in a clinical study in which febuxostat was administered. * Is completing Phase 3 Studies C02-009 or C02-010. * Must not have experienced any serious study drug-related adverse events in the previous study. * Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study Exclusion Criteria: * Has had any other significant medical condition as defined by the investigator that would interfere with the treatment, safety, or compliance with the protocol. * Is intolerant of allopurinol.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.

Timeframe: Month 1

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.

Timeframe: Month 12

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.

Timeframe: Month 24

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.

Timeframe: Month 36

Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.

Timeframe: Last Visit on treatment (up to 40 months).

Trial details

NCT IDNCT00175019

SponsorTakeda

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-02

Results submitted2009-03-12

View on ClinicalTrials.gov More Gout trials